    <SEC-DOCUMENT>0001213900-24-076184-index.html : 20240905
    <SEC-HEADER>0001213900-24-076184.hdr.sgml : 20240905
    <ACCEPTANCE-DATETIME>20240905171825
    ACCESSION NUMBER:		0001213900-24-076184
    CONFORMED SUBMISSION TYPE:	8-K
    PUBLIC DOCUMENT COUNT:		36
    CONFORMED PERIOD OF REPORT:	20240829
    ITEM INFORMATION:		Entry into a Material Definitive Agreement
    ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
    ITEM INFORMATION:		Results of Operations and Financial Condition
    ITEM INFORMATION:		Material Modifications to Rights of Security Holders
    ITEM INFORMATION:		Changes in Registrant's Certifying Accountant
    ITEM INFORMATION:		Changes in Control of Registrant
    ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
    ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    ITEM INFORMATION:		Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
    ITEM INFORMATION:		Change in Shell Company Status
    ITEM INFORMATION:		Regulation FD Disclosure
    ITEM INFORMATION:		Financial Statements and Exhibits
    FILED AS OF DATE:		20240905
    DATE AS OF CHANGE:		20240905

    FILER:

    	COMPANY DATA:
    		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
    		CENTRAL INDEX KEY:			0000907654
    		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
    		ORGANIZATION NAME:           	03 Life Sciences
    		IRS NUMBER:				363855489
    		STATE OF INCORPORATION:			DE
    		FISCAL YEAR END:			1231

    	FILING VALUES:
    		FORM TYPE:		8-K
    		SEC ACT:		1934 Act
    		SEC FILE NUMBER:	000-22873
    		FILM NUMBER:		241282218

    	BUSINESS ADDRESS:
    		STREET 1:		855 OAK GROVE AVE.
    		STREET 2:		SUITE 100
    		CITY:			MENLO PARK
    		STATE:			CA
    		ZIP:			94025
    		BUSINESS PHONE:		650-606-7910

    	MAIL ADDRESS:
    		STREET 1:		855 OAK GROVE AVE.
    		STREET 2:		SUITE 100
    		CITY:			MENLO PARK
    		STATE:			CA
    		ZIP:			94025

    	FORMER COMPANY:
    		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
    		DATE OF NAME CHANGE:	20090128

    	FORMER COMPANY:
    		FORMER CONFORMED NAME:	NUVELO INC
    		DATE OF NAME CHANGE:	20030203

    	FORMER COMPANY:
    		FORMER CONFORMED NAME:	HYSEQ INC
    		DATE OF NAME CHANGE:	19970610
    </SEC-HEADER>
    <DOCUMENT>
    <TYPE>8-K
    <SEQUENCE>1
    <FILENAME>ea0213193-8k_orukathera.htm
    <DESCRIPTION>CURRENT REPORT
    <TEXT>
    Document 1 - file: ea0213193-8k_orukathera.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.1
    <SEQUENCE>2
    <FILENAME>ea021319301ex3-1_oruka.htm
    <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024
    <TEXT>
    Document 2 - file: ea021319301ex3-1_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.2
    <SEQUENCE>3
    <FILENAME>ea021319301ex3-2_oruka.htm
    <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024
    <TEXT>
    Document 3 - file: ea021319301ex3-2_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.3
    <SEQUENCE>4
    <FILENAME>ea021319301ex3-3_oruka.htm
    <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024
    <TEXT>
    Document 4 - file: ea021319301ex3-3_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.4
    <SEQUENCE>5
    <FILENAME>ea021319301ex3-4_oruka.htm
    <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE SEPTEMBER 3, 2024
    <TEXT>
    Document 5 - file: ea021319301ex3-4_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.5
    <SEQUENCE>6
    <FILENAME>ea021319301ex3-5_oruka.htm
    <DESCRIPTION>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, FILED SEPTEMBER 3, 2024
    <TEXT>
    Document 6 - file: ea021319301ex3-5_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.6
    <SEQUENCE>7
    <FILENAME>ea021319301ex3-6_oruka.htm
    <DESCRIPTION>AMENDED AND RESTATED BYLAWS OF THE COMPANY
    <TEXT>
    Document 7 - file: ea021319301ex3-6_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.8
    <SEQUENCE>8
    <FILENAME>ea021319301ex3-8_oruka.htm
    <DESCRIPTION>FORM OF CERTIFICATE OF ELIMINATION OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK, EFFECTIVE AUGUST 29, 2024
    <TEXT>
    Document 8 - file: ea021319301ex3-8_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-3.9
    <SEQUENCE>9
    <FILENAME>ea021319301ex3-9_oruka.htm
    <DESCRIPTION>FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK, EFFECTIVE AUGUST 29, 2024
    <TEXT>
    Document 9 - file: ea021319301ex3-9_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.10
    <SEQUENCE>10
    <FILENAME>ea021319301ex10-10_oruka.htm
    <DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 STOCK INCENTIVE PLAN
    <TEXT>
    Document 10 - file: ea021319301ex10-10_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.11
    <SEQUENCE>11
    <FILENAME>ea021319301ex10-11_oruka.htm
    <DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN
    <TEXT>
    Document 11 - file: ea021319301ex10-11_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.13
    <SEQUENCE>12
    <FILENAME>ea021319301ex10-13_oruka.htm
    <DESCRIPTION>SECOND AMENDMENT TO AMENDED AND RESTATED ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN, EFFECTIVE AS OF MAY 7, 2024
    <TEXT>
    Document 12 - file: ea021319301ex10-13_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.16
    <SEQUENCE>13
    <FILENAME>ea021319301ex10-16_oruka.htm
    <DESCRIPTION>FORM OF EMPLOYEE WARRANT AGREEMENT
    <TEXT>
    Document 13 - file: ea021319301ex10-16_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.25
    <SEQUENCE>14
    <FILENAME>ea021319301ex10-25_oruka.htm
    <DESCRIPTION>CONSULTING AGREEMENT, EFFECTIVE AS OF AUGUST 30, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND JEFF DEKKER
    <TEXT>
    Document 14 - file: ea021319301ex10-25_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-14.1
    <SEQUENCE>15
    <FILENAME>ea021319301ex14-1_oruka.htm
    <DESCRIPTION>CODE OF BUSINESS CONDUCT AND ETHICS OF ORUKA THERAPEUTICS, INC
    <TEXT>
    Document 15 - file: ea021319301ex14-1_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-16.1
    <SEQUENCE>16
    <FILENAME>ea021319301ex16-1_oruka.htm
    <DESCRIPTION>LETTER FROM KPMG LLP, DATED SEPTEMBER 5, 2024
    <TEXT>
    Document 16 - file: ea021319301ex16-1_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-21.1
    <SEQUENCE>17
    <FILENAME>ea021319301ex21-1_oruka.htm
    <DESCRIPTION>LIST OF SUBSIDIARIES OF ORUKA THERAPEUTICS, INC
    <TEXT>
    Document 17 - file: ea021319301ex21-1_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-99.1
    <SEQUENCE>18
    <FILENAME>ea021319301ex99-1_oruka.htm
    <DESCRIPTION>PRESS RELEASE, ISSUED ON SEPTEMBER 3, 2024
    <TEXT>
    Document 18 - file: ea021319301ex99-1_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-99.2
    <SEQUENCE>19
    <FILENAME>ea021319301ex99-2_oruka.htm
    <DESCRIPTION>AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024
    <TEXT>
    Document 19 - file: ea021319301ex99-2_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-99.3
    <SEQUENCE>20
    <FILENAME>ea021319301ex99-3_oruka.htm
    <DESCRIPTION>UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024
    <TEXT>
    Document 20 - file: ea021319301ex99-3_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-99.4
    <SEQUENCE>21
    <FILENAME>ea021319301ex99-4_oruka.htm
    <DESCRIPTION>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024
    <TEXT>
    Document 21 - file: ea021319301ex99-4_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-99.5
    <SEQUENCE>22
    <FILENAME>ea021319301ex99-5_oruka.htm
    <DESCRIPTION>UNAUDITED PRO FORMA FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. AND ARCA BIOPHARMA, INC. AS OF JUNE 30, 2024 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024, AS WELL AS FOR THE YEAR ENDED DECEMBER 31, 2023
    <TEXT>
    Document 22 - file: ea021319301ex99-5_oruka.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>23
    <FILENAME>ex14-1_001.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 23 - file: ex14-1_001.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-101.SCH
    <SEQUENCE>24
    <FILENAME>orka-20240829.xsd
    <DESCRIPTION>XBRL SCHEMA FILE
    <TEXT>
    Document 24 - file: orka-20240829.xsd

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-101.DEF
    <SEQUENCE>25
    <FILENAME>orka-20240829_def.xml
    <DESCRIPTION>XBRL DEFINITION FILE
    <TEXT>
    Document 25 - file: orka-20240829_def.xml

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-101.LAB
    <SEQUENCE>26
    <FILENAME>orka-20240829_lab.xml
    <DESCRIPTION>XBRL LABEL FILE
    <TEXT>
    Document 26 - file: orka-20240829_lab.xml

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-101.PRE
    <SEQUENCE>27
    <FILENAME>orka-20240829_pre.xml
    <DESCRIPTION>XBRL PRESENTATION FILE
    <TEXT>
    Document 27 - file: orka-20240829_pre.xml

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>XML
    <SEQUENCE>29
    <FILENAME>R1.htm
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 29 - file: R1.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EXCEL
    <SEQUENCE>30
    <FILENAME>Financial_Report.xlsx
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 30 - file: Financial_Report.xlsx

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>XML
    <SEQUENCE>31
    <FILENAME>Show.js
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 31 - file: Show.js

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>XML
    <SEQUENCE>32
    <FILENAME>report.css
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 32 - file: report.css

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>XML
    <SEQUENCE>34
    <FILENAME>FilingSummary.xml
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 34 - file: FilingSummary.html

    Document 34 - RAW XML: FilingSummary.xml

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>JSON
    <SEQUENCE>36
    <FILENAME>MetaLinks.json
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 36 - file: MetaLinks.json

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>ZIP
    <SEQUENCE>37
    <FILENAME>0001213900-24-076184-xbrl.zip
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 37 - file: 0001213900-24-076184-xbrl.zip

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>XML
    <SEQUENCE>38
    <FILENAME>ea0213193-8k_orukathera_htm.xml
    <DESCRIPTION>IDEA: XBRL DOCUMENT
    <TEXT>
    Document 38 - file: ea0213193-8k_orukathera_htm.html

    Document 38 - RAW XML: ea0213193-8k_orukathera_htm.xml

    </DOCUMENT>
    </SEC-DOCUMENT>